SCHEMBL4237344

SCHEMBL4237344

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)C(C)OC)cc2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.58
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
FPR2 P25090 1/20 0.46
MAPT P10636 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MTNR1B P49286 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MCHR1 Q99705 1/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ANPEP P15144 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149842 0.87 PKM (0.63) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4233456 0.87 PKM (0.63) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4683708 0.87 PKM (0.63) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4228811 0.85 PKM (0.60) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4226971 0.85 PKM (0.60) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4232198 0.84 PKM (0.54) PKMTAS1R3TAS1R1FPR2MAPT
Ammonia Solution, Strong SCHEMBL4235457 0.84 PKM (0.58) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4238753 0.83 CYP1A2 (0.59) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4229112 0.83 PKM (0.57) PKMTAS1R3TAS1R1FPR2MAPT
SCHEMBL4686340 0.83 KDR (0.52) PKMMAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.